🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  2. Cognitive Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  3. Cognitive Behavioral Therapy (CBT)

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post Traumatic

    phase 2 other completed

    1 trial

  4. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  5. DEFLAN 22,75 mg/ml gocce orali, sospensione

    Sana Biotechnology

    Laminopathies

    phase 2 small molecule active

    1 trial

  6. DNL593

    Denali Therapeutics

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial

  7. Darleukin, Fibromun

    Philogen S.p.A.

    Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.

    phase 2 small molecule active

    1 trial

  8. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  9. ETIDRONATE DISODIUM ORAL CAPSULES 400 MG PLACEBO, ETIDRONATE DISODIUM ORAL CAPSULES 400 MG

    Disc Medicine

    Fahr's disease, Fahr's syndrome

    phase 2 small molecule active

    1 trial

  10. Enema transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  11. Epidyolex 100 mg/ml oral solution

    Pari Pharma GmbH

    Children and adolescents with severe neurodevelopmental disorders

    phase 2 small molecule active

    1 trial

  12. Etrinabdione oral solution

    Wuhan Createrna Science and Technology Co., Ltd

    Peripheral Arterial Disease

    phase 2 small molecule active

    1 trial

  13. Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  14. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  15. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  16. Fycompa 2 mg film-coated tablets, Fycompa 2 mg film-coated tablets, Fycompa 0.5 mg/ml oral suspension, Fycompa 2 mg film-coated tablets

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  17. GIOTRIF 40 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 20 mg film-coated tablets

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  18. GLPG0259 oral capsule

    Lakefront Biotherapeutics NV

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  19. Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  20. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Glioblastoma

    phase 2 small molecule active

    1 trial

  21. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  22. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  23. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  24. Ifetroban Oral Capsule

    CUMBERLAND PHARMACEUTICALS INC

    Asthma, Aspirin-Induced

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources